Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness

Banu Turgut Ozturk, Banu Bozkurt, Hurkan Kerimoglu, Mehmet Okka, Umit Kamis, Kemal Gunduz, Banu Turgut Ozturk, Banu Bozkurt, Hurkan Kerimoglu, Mehmet Okka, Umit Kamis, Kemal Gunduz

Abstract

Purpose: To investigate the role of serum inflammatory cytokines and vascular endothelial growth factor (VEGF) in diabetic retinopathy (DR) and evaluate their relationship with macular thickness measurements obtained with optical coherence tomography (OCT).

Methods: The study enrolled 28 healthy subjects (Group 1), 31 patients without DR (Group 2), 49 patients with nonproliferative DR (Group 3), and 46 patients with proliferative DR (Group 4). Macular profile was assessed with Stratus OCT-3 and the serum concentrations of VEGF and interleukin-1 alpha (IL-1 alpha), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), macrophage inflammatory protein (MIP-1 alpha), monocyte chemoattractant protein (MCP-1), and epidermal growth factor (EGF) were measured using multiplex bead immunoassay.

Results: The median value of the visual acuity was 20/20 (Groups 1 and 2), and 20/100 (Group 3), and 20/125 (Group 4). The median value of central subfield macular thickness was estimated as 165.50 microm in Group 1, 202.5 microm in Group 2, 318 microm in Group 3, and 310 microm in Group 4. The median serum VEGF level, which was 98.20 pg/ml in Group 1, demonstrated a progressive rise to 125.37 pg/ml in Group 2, to 153.07 pg/ml in Group 3, and to 149.12 pg/ml in Group 4. Statistical significance was found between all groups (p<0.05) except between Groups 3 and 4 (p=0.87). The median levels of IL-1 alpha and IL-6 were zero in all groups. The median serum levels of IL-8, IL-10, MIP-1 alpha, and EGF revealed a wide range within each group but no statistical significance between the groups (p>0.05). The median serum levels of IL-8, IL-10, MIP-1 alpha, and EGF revealed a wide range within each group, however, no statistically significant relationship was found between the groups (p>0.05). The median values of the serum MCP-1 concentrations presented a statistically significant rise with the progression of DR (p=0.02). No correlation was found between macular thickness and serum cytokine and VEGF levels (p>0.05).

Conclusions: Increased serum levels of VEGF and MCP-1 may act as a key regulator of DR and provide a potential tool for risk assessment in diabetic patients. Further studies that evaluate both vitreous and serum levels in various stages of DR are needed to provide a better understanding of the interaction between systemic and local inflammatory and angiogenic factors.

Figures

Figure 1
Figure 1
Distribution of serum VEGF concentrations within the groups. Boxplot analysis showing increased serum levels of vascular endothelial growth factor (VEGF) in patients with diabetes mellitus (DM) compared to control subjects. The median serum VEGF levels were higher in diabetic subjects with retinopathy than those without. Abbreviations: DR(-) represents patients without diabetic retinopathy.
Figure 2
Figure 2
Distribution of serum MCP-1 levels within the groups. Boxplot analysis of serum monocyte chemoattractant protein (MCP-1) levels in diabetic patients demonstrated an increase with progression of diabetic retinopathy (DR). Abbreviations: DR(-) represents patients without diabetic retinopathy.

References

    1. Klein R, Klein BEK, Moss SE, Davis MD, Demets DL. The Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology. 1984;91:1464–74.
    1. Clark JB, Grey RH, Lim KK, Burns-Cox CJ. Loss of vision before ophthalmic referral in blind and partially sighted diabetics in Bristol. Br J Ophthalmol. 1994;78:741–4.
    1. Perkovich BT, Meyers SM. Systemic factors affecting diabetic amcular edema. Am J Ophthalmol. 1988;105:211–2.
    1. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XI. The incidence of macular edema. Ophthalmology. 1989;96:1501–10.
    1. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54:1–32.
    1. Meyer CH. Current treatment approaches in diabetic macular edema. Ophthalmologica. 2007;221:118–31.
    1. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;86:363–5.
    1. Patel JI, Tombran-Tink J, Hykin PG, Gregor ZJ, Cree IA. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Exp Eye Res. 2006;82:798–806.
    1. Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, van Damme J. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw. 2006;17:155–65.
    1. Hernández C, Sequra RM, Fonollosa A, Carrasco E, Francisco G, Simo R. Interleukin−8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med. 2005;22:719–22.
    1. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods. 2000;243:243–55.
    1. Dupont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol. 2005;66:175–91.
    1. Ray CA, Bowsher RR, Smith WC, Devanarayan V, Willey MB, Brandt JT, Dean RA. Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum. J Pharm Biomed Anal. 2005;36:1037–44.
    1. Wilkinson CP, Ferris FL, 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–82.
    1. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H, Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology. 2008;115:1366–71.
    1. The Eye Diseases Prevalence Research Group Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–85.
    1. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent DM. N Engl J Med. 1993;329:977–86.
    1. Moore J, Bagley S, Ireland G, McLeod D, Boulton ME. Three dimensional analysis of microaneurysms in the human diabetic retina. J Anat. 1999;194:89–100.
    1. Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, Kishi S. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications. 2001;15:257–9.
    1. Doganay S, Evereklioglu C, Er H, Turkoz Y, Sevinc A, Mehmet N, Savlı H. Comparison of serum NO, TNF-α, IL-1β, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye. 2002;16:163–70.
    1. Maier R, Weger M, Haller-Schober EM, El-Shabrawi Y, Wedrich A, Theisl A, Aigner R, Barth A, Haas A. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol Vis. 2008;14:637–43.
    1. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis AP. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101:1219–24.
    1. Minchenko A, Salceda S, Bauer T, Caro J. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res. 1994;40:35–9.
    1. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res. 1997;64:505–17.
    1. Nguyen QD, Tatlıpınar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA. Vascular Enodthelial Growth Factor Is a Critical Stimulus for Diabetic Macular Edema. Am J Ophthalmol. 2006;142:961–9.
    1. Cavusoglu AC, Bilgili S, Alaluf A, Doğan A, Yilmaz F, Aslanca D, Karaca B, Yüksel B, Topaloglu E. Vascular endothelial growth factor level in the serum of diabetic patients with retinopathy. Ann Ophthalmol (Skokie) 2007;39:205–8.
    1. Petrovic MG, Korosec P, Kosnik M, Osredkar J, Hawlina M, Peterlin B, Petrovic D. Local and Genetic Determinants of Vascular Endothelial Growth Factor Expression in Advanced Proliferative Diabetic Retinopathy. Mol Vis. 2008;14:1382–7.
    1. Meleth AD, Agron E, Chan C, Reed GF, Arora K, Byrnes G, Csaky KG, Ferris FL, III, Chew EY. Serum Inflammatory Markers in Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2005;46:4295–301.
    1. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271:736–41.
    1. Maruo N, Morita I, Shirao M, Murota S. IL-6 increases endothelial permeability in vitro. Endocrinology. 1992;131:710–4.
    1. Lee JH, Lee W, Kwon OH, Kim JH, Kwon OW, Kim KH, Lim JB. Cytokine profile of peripheral blood in type 2 diabetes mellitus patients with diabetic retinopathy. Ann Clin Lab Sci. 2008;38:361–7.
    1. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res. 1995;14:1045–53.
    1. Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P, Muthukkaruppan V. Proinflammatory Cytokines and Angiogenic and Anti-angiogenic Factors in Vitreous of Patients with Proliferative Diabetic Retinopathy and Eales Disease. Retina. 2008;28:817–24.
    1. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and antiinflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dryeye disease. Invest Ophthalmol Vis Sci. 2001;42:2283–92.
    1. Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol. 1993;11:165–90.
    1. Taub DD. Chemokine-leukocyte interactions. The voodoo that they do so well. Cytokine Growth Factor Rev. 1996;7:355–76.
    1. Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 1989;169:1485–90.
    1. Jo N, Wu GS, Rao NA. Upregulation of chemokine expression in the retinal vasculature in ischemia-reperfusion injury. Invest Ophthalmol Vis Sci. 2003;44:4054–60.
    1. Takaishi H, Taniguchi T, Takahashi A, Ishikawa Y, Yokoyama M. High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells. Biochem Biophys Res Commun. 2003;305:122–8.
    1. Mitamura Y, Takeuchi S, Matsuda A, Tagawa Y, Mizue Y, Nishihira J. Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy. Ophthalmologica. 2001;215:415–8.
    1. Scannell G, Waxman K, Kaml GJ, Ioli G, Gatagana T, Yamamoto R, Granger GA. Hypoxia induces a human macrophage cell line to release tumor necrosis factor-alpha and its soluble receptors in vitro. J Surg Res. 1993;54:281–5.
    1. Yoshida S, Yoshida A, Ishibashi T, Elner SG, Elner VM. Role of MCP-1and MIP-1 alpha in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization. J Leukoc Biol. 2003;73:137–44.
    1. Hanifi-Moghaddam P, Kappler S, Seissler J. Müller –Scholze S, Martin S, Roep BO, Strassburger K, Kolb H, Schlott NC. Altered chemokine levels in individuals et risk of Type 1 diabetes mellitus. Diabet Med. 2006;23:156–63.
    1. Capeans C, De Rojas MV, Lojo S, Salorio MS. C–C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina. 1998;18:546–50.
    1. Boulton M, Gregor Z, McLeod D, Charteris D, Jarvis-Evans J, Moriarty P, Khaliq A, Foreman D, Allamby D, Bardsley B. Intravitreal growth factors in proliferative diabetic retinopathy: Correlation with neovascular activity and glycaemic management. Br J Ophthalmol. 1997;81:228–33.
    1. McAvoy JW, Chamberlain CG. Growth factors in the eye. Prog Growth Factor Res. 1990;2:29–43.
    1. Patel B, Hiscott P, Charteris D, Mather J, McLeod D, Boulton M. Retinal and preretinal localisation of epidermal growth factor, transforming growth factor alpha, and their receptor in proliferative diabetic retinopathy. Br J Ophthalmol. 1994;78:714–8.
    1. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116:73–9.
    1. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19:433–42.
    1. Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet. 2005;366:2058–61.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅